Evaluating a new imaging method for Thyroid Eye Disease
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
NA · Peking University Third Hospital · NCT06359795
This study is testing a new imaging method to see if it can better assess the activity of Thyroid Eye Disease compared to the traditional imaging technique for patients with this condition.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06359795 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) compared to the traditional 99mTc-DTPA SPECT/CT. Patients diagnosed with TED will undergo both imaging techniques within a 10-day period to evaluate their diagnostic accuracy and ability to assess therapy response. The study will quantify uptake in the extraocular muscles and correlate these metrics with clinical activity data to determine the superiority of the new imaging method. The goal is to enhance the diagnosis and management of TED through improved imaging techniques.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been diagnosed with Thyroid Eye Disease.
Not a fit: Patients with severe liver or kidney dysfunction, or those unable to cooperate with the imaging procedures, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate assessments and better management of Thyroid Eye Disease for patients.
How similar studies have performed: While FAPI PET has shown promise in other fibroinflammatory conditions, this specific application for Thyroid Eye Disease is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Patients diagnosed with TED; 3. Complete understanding and voluntary participation in this study, with the signing of an informed consent form. Exclusion Criteria: 1. Severe liver or kidney dysfunction; 2. Inability to maintain a supine position for 5 minutes to cooperate with the examination; 3. Suffering from claustrophobia or other psychiatric disorders; 4. Patients planning pregnancy or in the prenatal or lactation period; 5. Other conditions deemed unsuitable for participation in the trial by the investigator.
Where this trial is running
Beijing, Beijing Municipality
- Dept. of Nuclear Medicine, Peking University Third Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Hui Li, Dr. — Peking University Third Hospital
- Study coordinator: Hui Li, Dr.
- Email: huilee1990@163.com
- Phone: 86-13121136769
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thyroid Eye Disease